STN ‐ DBS : Pre‐Synaptic Stimulation Causes Post‐Synaptic Inhibition

Subthalamic nucleus deep brain stimulation (STN-DBS) is a highly effective therapy for advanced Parkinson's disease, but its mechanism remains unresolved.1 Because stimulation artifacts confound standard electrophysiology, human recordings have not supported a simple model of uniform STN neuronal inhibition during stimulation.2 As a result, competing models (net STN inhibition, fiber-specific disruption, or “information jamming”) have lacked a direct, in vivo test at stimulation site. An in vivo, transmitter-level mechanism linking DBS to local synaptic and neuronal effects has been missing: direct glutamate/GABA measurements during stimulation can now test elements of this hypothesized mechanism.3 Li et al.4 paired clinically relevant STN-DBS (monopolar, monophasic cathodic pulses at 130 Hz) with fiber photometry and genetically encoded sensors that report (i) calcium in STN neurons, (ii) calcium in glutamatergic (cortical) and GABAergic (pallidal) terminals, and (iii) extracellular glutamate and GABA in the STN region. In freely-moving mice, DBS elicited a transient rise followed by sustained, current-dependent suppression of STN activity, despite sustained increases in afferent terminal calcium. Mechanistically, DBS depressed both glutamate and GABA signals, but reduced glutamate more consistently, shifting the local excitation/inhibition balance toward inhibition offering a mechanism for STN silencing. STN-DBS dissociates presynaptic recruitment from postsynaptic output. These signatures held in 6-OHDA mice, depended on stimulation frequency (20 Hz was ineffective), and inspired “chemogenetic DBS”. Here, instead of delivering electrical pulses, the authors used an engineered inhibitory receptor to selectively reduce STN neuron activity (Gi-DREADD), showing that STN inhibition improved motor behavior whereas excitation did not. Motor rescue was also observed in MitoPark mice (a genetic, progressive model characterized by degeneration of dopaminergic neurons). These discoveries make a compelling case that STN inhibition is a therapeutic lever for parkinsonism, and that 130 Hz STN-DBS achieves it by tipping local STN input balance toward inhibition (reducing more glutamatergic than GABAergic drive), yielding net STN silencing and motor improvement. Beyond clarification across competing mechanistic theories,5 there is a key methodological advance: transmitter-level readouts provide a framework to compare how stimulation settings (pulse width, polarity, waveform, or frequency) and topographic choices reshape glutamate/GABA balance and STN output. It is also possible to test whether distinct “parameter signatures” align with symptom domains (eg, whether 60–80 Hz stimulation for axial symptoms recruits similar mechanisms across sites). One highly impactful and testable question is whether beta-band biomarkers in adaptive DBS truly mark attainment of a suppressive STN state; resolving this would anchor beta suppression to local physiology and refine closed-loop control. Translation remains limited: findings are from rodents and using non-deployable chemogenetics. Even so, this work supports STN inhibition as a therapeutic target and motivates leveraging next-generation DBS sensing to identify parameter regimens most likely to achieve this suppressive state in each patient. (1) Manuscript Preparation: A. Writing of the First Draft, B. Review and Critique. M.D.M.: 1A, 1B. R.B.: 1A, 1B. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.